Background Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal
type I collagen bone matrix which typically results in multiple fractures with little or no …

Calcium supplementation for improving bone mineral density in children - Winzenberg, TM - 2006
| Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience …

Background. Adults with osteogenesis imperfecta (OI) have a high risk of fracture. Currently,
few treatment options are available, and bone anabolic therapies have not been tested in …

A 2‐year prospective, partially randomized open‐label trial comparing oral alendronate with
intravenous pamidronate therapy in children with OI showed equivalence in increasing total …

Abstract Background/Aims: To systematically assess contemporary knowledge regarding the
effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta …

OBJECTIVE: To evaluate the functional abilities and the level of ambulation during
pamidronate therapy in children with moderate to severe osteogenesis imperfecta. STUDY …

Epidemiological evidence suggests that bisphosphonates are the most promising drugs for
patients with osteogenesis imperfecta (OI). However, data on this issue are controversial …

This systematic review of the effects of bisphosphonate treatment in children with
osteogenesis imperfecta was conducted using the American Academy for Cerebral Palsy …

Purpose Osteogenesis imperfecta (OI) predisposes people to recurrent fractures, bone
deformities, and short stature. There is a lack of large-scale systematic studies that have …

Bisphosphonates are currently used in the treatment of osteoporosis (postmenopausal and
steroid-induced), hypercalcemia of malignancy, Paget's disease of bone, multiple myeloma …